Zydus Lifesciences Limited has informed the Exchange about General Updates

Regulatory & Legal View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.3%Reaction day

₹902.40

prior close

₹902.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+0.8%+0.5% vs market

Pharmaceuticals peers, median of 156sector+0.8%+0.5% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty 100 and 0.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.4

10m

+0.3

15m

+0.5

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.3+0.8+0.5+0.8+0.5

Next day

+1.5+0.9+0.6+0.7+0.7

+1.7+1.7+0.1+1.9-0.2

+2.2+1.4+0.8+1.4+0.8

+3.2+1.2+2.0+1.3+1.9

+2.8+1.1+1.7+2.1+0.8

-1.0-0.9-0.1-1.1+0.1

15d

-1.8-2.3+0.5-4.3+2.5

-2.8-3.1+0.4-5.4+2.7

+0.3-3.5+3.8-7.2+7.6

-4.0-12.1+8.1-13.0+9.0

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences has received an order from the Assistant Commissioner of State Tax, Gujarat under Section 74 of the CGST Act, 2017, raising a demand of Rs. 2.8 crore (including interest and penalty) for financial year 2018-19. The issue relates to allegedly inadmissible availment of Input Tax Credit. The company has stated it intends to appeal the order and is hopeful of a favourable outcome based on past High Court and Supreme Court precedents on similar matters. The company has clarified that there is no material financial impact from this order.

Likely market impact

The Rs. 2.8 crore demand is small relative to Zydus Lifesciences' overall scale, and the company's confidence in winning on appeal limits the near-term concern. Shareholders are unlikely to see any meaningful effect on the stock, though the appeal outcome bears watching.